These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 10698518)
1. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518 [TBL] [Abstract][Full Text] [Related]
2. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Perissi V; Menini N; Cottone E; Capello D; Sacco M; Montaldo F; De Bortoli M Oncogene; 2000 Jan; 19(2):280-8. PubMed ID: 10645007 [TBL] [Abstract][Full Text] [Related]
3. An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Bates NP; Hurst HC Oncogene; 1997 Jul; 15(4):473-81. PubMed ID: 9242384 [TBL] [Abstract][Full Text] [Related]
4. Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region. Orso F; Cottone E; Hasleton MD; Ibbitt JC; Sismondi P; Hurst HC; De Bortoli M Biochem J; 2004 Jan; 377(Pt 2):429-38. PubMed ID: 14565844 [TBL] [Abstract][Full Text] [Related]
5. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Vernimmen D; Begon D; Salvador C; Gofflot S; Grooteclaes M; Winkler R Biochem J; 2003 Feb; 370(Pt 1):323-9. PubMed ID: 12418962 [TBL] [Abstract][Full Text] [Related]
6. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells. Hua G; Zhu B; Rosa F; Deblon N; Adélaïde J; Kahn-Perlès B; Birnbaum D; Imbert J Mol Cancer Res; 2009 Mar; 7(3):402-14. PubMed ID: 19276186 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995 [TBL] [Abstract][Full Text] [Related]
8. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Turner BC; Zhang J; Gumbs AA; Maher MG; Kaplan L; Carter D; Glazer PM; Hurst HC; Haffty BG; Williams T Cancer Res; 1998 Dec; 58(23):5466-72. PubMed ID: 9850080 [TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759 [TBL] [Abstract][Full Text] [Related]
10. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Shah RN; Ibbitt JC; Alitalo K; Hurst HC Oncogene; 2002 Nov; 21(54):8251-61. PubMed ID: 12447688 [TBL] [Abstract][Full Text] [Related]
12. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance]. Yang JQ; Chen L; Xing TY Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828 [TBL] [Abstract][Full Text] [Related]
13. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Macaluso M; Cinti C; Russo G; Russo A; Giordano A Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of the oxytocin promoter by oestrogens uses a novel non-classical mechanism of oestrogen receptor action. Koohi MK; Ivell R; Walther N J Neuroendocrinol; 2005 Apr; 17(4):197-207. PubMed ID: 15842231 [TBL] [Abstract][Full Text] [Related]
15. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Ohtake F; Takeyama K; Matsumoto T; Kitagawa H; Yamamoto Y; Nohara K; Tohyama C; Krust A; Mimura J; Chambon P; Yanagisawa J; Fujii-Kuriyama Y; Kato S Nature; 2003 May; 423(6939):545-50. PubMed ID: 12774124 [TBL] [Abstract][Full Text] [Related]
16. Expression of the human oestrogen receptor-alpha gene is regulated by promoter F in MG-63 osteoblastic cells. Lambertini E; Penolazzi L; Giordano S; Del Senno L; Piva R Biochem J; 2003 Jun; 372(Pt 3):831-9. PubMed ID: 12659635 [TBL] [Abstract][Full Text] [Related]
17. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Hyder SM; Nawaz Z; Chiappetta C; Stancel GM Cancer Res; 2000 Jun; 60(12):3183-90. PubMed ID: 10866309 [TBL] [Abstract][Full Text] [Related]
18. Interaction of oestrogen and peroxisome proliferator-activated receptors with apolipoprotein(a) gene enhancers. Puckey LH; Knight BL Biochem J; 2002 Aug; 366(Pt 1):157-63. PubMed ID: 12023905 [TBL] [Abstract][Full Text] [Related]
19. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Hurtado A; Holmes KA; Geistlinger TR; Hutcheson IR; Nicholson RI; Brown M; Jiang J; Howat WJ; Ali S; Carroll JS Nature; 2008 Dec; 456(7222):663-6. PubMed ID: 19005469 [TBL] [Abstract][Full Text] [Related]
20. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]